LTRN is navigating a uniquely charged 48 hours: a registered direct offering announced this morning collides with Q1 results due Thursday, all while short interest holds near a multi-month peak and the borrow market sits materially tighter than it did just six weeks ago.
The immediate headline is the capital raise. Lantern Pharma announced Wednesday a registered direct offering of up to $9.25 million, priced with existing holders and a single unnamed institutional investor. The deal is expected to close May 14 — the day before the earnings print. That sequencing matters. The company is effectively locking in fresh cash before the market sees its first-quarter numbers, which can read as either prudent cash management for a pre-revenue AI drug-discovery platform or a signal that management wanted runway secured before results were absorbed.
Short interest tells a story of rapid repositioning over the past month. Bears have more than doubled their positions since early April. SI % of free float has climbed from roughly 9-10% in the April 7-9 window all the way to 23.3% now — a 120% rise in just over five weeks. The pace of that build slowed this week, with SI edging down about 7% from its mid-week high, but the level is still among the highest readings in this data window. The ORTEX short score of 80.3 puts the stock in the top tier of short-side pressure across the universe, and the factor rank on short score percentile is just 3 — meaning nearly every comparable stock has a lower short score. Days to cover run at 7.4, so any sharp covering move would take time to clear.
The lending market adds texture to that picture. Cost to borrow has eased dramatically from its early-April extreme — rates peaked above 225% annualised on April 1, collapsed to 22.6% this week as availability loosened with the short build. Availability is running at roughly 32-35% of outstanding short interest based on the data window, which is tight but not critically so. The borrow market is not in crisis mode, but it is not cheap either, and at 22.6% CTB, anyone initiating a new short position is paying a material carry cost. The 52-week utilization peak of 97.4% — versus 68.3% today — shows the lending pool has room to absorb more if demand picks up again.
Options positioning is notably call-skewed for a stock this heavily shorted. The put/call ratio of 0.27 is below its 20-day average of 0.33, leaving the z-score at –0.55. That's modestly bullish relative to recent norms — not extreme, but the contrast with a 23% short float is striking. The PCR touched a 52-week low of 0.049 earlier in April during what was likely the run-up in the stock price. It has since normalised but remains call-heavy. That gap between options sentiment and short positioning sets up a potential tug-of-war around Thursday's results.
The pipeline driving all of this activity is Lantern's AI drug-discovery platform. This week the company unveiled a roadmap for withZeta.ai, its multi-agentic "co-scientist" featuring what it calls ZetaSwarm and ZetaOmics capabilities. Late April saw the debut of an expanded predictBBB.ai web service for drug developers. Both announcements generated meaningful news flow and likely contributed to the April stock recovery — LTRN is up 4.6% on the month despite a 4.6% slide this week. The March 30 earnings reaction, where the stock jumped 22% on the day and 44% over the following five sessions, remains the key historical reference point. A repeat of that kind of move — in either direction — at Thursday's Q1 print would be the most relevant outcome to watch given the size of the short book sitting in the stock.
Analyst coverage is sparse and dated. Lake Street initiated with a Buy and a $25 target in April 2025, which has not been updated since. Given the stock now trades at $2.06, the gap between that target and the current price is too wide to take at face value without a fresh note. The angle to watch Thursday is less about whether Lantern hits a revenue number — the company has minimal revenues — and more about what management says on the withZeta.ai commercialisation timeline and whether the $9.25 million raise buys enough runway to reach the next meaningful data catalyst.
See the live data behind this article on ORTEX.
Open LTRN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
